Conference Coverage

Survival after TAVR superior to surgery in high-risk aortic stenosis patients


 

FROM ACC14

The study was published simultaneously in the New England Journal of Medicine on March 29 (2014 March 29 [doi:10.1056/NEJMoa1400590]).

The study is funded by the CoreValve manufacturer, Medtronic. Dr. Adams disclosed receiving grant support from Medtronic during the conduct of the study and other support from Medtronic and Edwards Lifesciences outside the submitted work.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Latest heart failure guidelines break new ground
MDedge Cardiology
Medicare to cover cardiac rehab for some HF patients
MDedge Cardiology
HFPEF’s diverse features pose management and trial challenges
MDedge Cardiology
Post-LVAD acute kidney injury is predictor of all-cause mortality
MDedge Cardiology
Physician/patient communication on ICDs deemed problematic
MDedge Cardiology
First guidelines on pulmonary hypertension in sickle cell disease released
MDedge Cardiology
MicroRNA MIR-25 found to play key role in heart failure
MDedge Cardiology
Higher MAP target fails to improve sepsis survival
MDedge Cardiology
What’s new in non-STEMI management
MDedge Cardiology
FDA panel rejects serelaxin approval for heart failure, but urges future study
MDedge Cardiology

Related Articles